Human Epilepsy Project 3

Prior treatment

• History of previous or current significant psychiatric disorder that would interfere with study requirements
  • Cohort 2: Longstanding Treatment Responsive
• History of previous or current significant psychiatric disorder that would interfere with study requirements
  • Cohort 3: Longstanding IGE, Treatment Resistant
• History of previous or current significant psychiatric disorder that would interfere with study requirements
• History of/suspicion of provoked seizures accounting for 25% or more of seizures over the prior 2 years (eg alcohol, non-adherence, significant sleep deprivation).

Other illness

• Focal epilepsy
• Generalized/focal epilepsy mixed syndromes
• Progressive neurological disorder (brain tumor, Alzheimer's disease, progressive myoclonic epilepsy, etc.)
• Major medical co-morbidities (e.g. renal failure requiring dialysis, metastatic cancer, HIV, or significant liver or renal disease)
• Autism Spectrum Disorder
• History of chronic drug or alcohol abuse (misuse or excessive use that interferes with activities of daily living) within the last 2 years
• Seizures only during pregnancy
• Focal epilepsy
• Paroxysmal nonepileptic seizures
• Generalized/focal epilepsy mixed syndromes
• Progressive neurological disorder (brain tumor, Alzheimer's disease, progressive myoclonic epilepsy, etc.)
• Major medical co-morbidities (e.g. renal failure requiring dialysis, metastatic cancer, HIV, or significant liver or renal disease)
• Autism Spectrum Disorder
• History of chronic drug or alcohol abuse (misuse or excessive use that interferes with activities of daily living) within the last 2 years
• Seizures only during pregnancy
• Focal epilepsy
• Paroxysmal nonepileptic seizures
• Generalized/focal epilepsy mixed syndromes
• Progressive neurological disorder (brain tumor, Alzheimer's disease, progressive myoclonic epilepsy, etc.)
• Major medical co-morbidities (e.g. renal failure requiring dialysis, metastatic cancer, HIV, or significant liver or renal disease)
• Autism Spectrum Disorder
• History of chronic drug or alcohol abuse (misuse or excessive use that interferes with activities of daily living) within the last 2 years
• Seizures only during pregnancy

Other

• Epileptic or developmental encephalopathy
• Epileptic or developmental encephalopathy
• Epileptic or developmental encephalopathy

• Age ≥13 years at time of enrollment
• Age ≥8 years at time of seizure onset
• Clinical seizure(s) and history consistent with IGE. The only permitted seizure types are absence, myoclonus or generalized tonic-clonic convulsions
• Occurrence of at least 1 seizure of any type in the 6 months prior to treatment
• Patients must have one of the following:
  • GTCSs alone accompanied by generalized spike-wave consistent with IGE per adjudication review
  • GTCSs with a history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review
  • GTCSs associated with a history of absence and/or myoclonus, not accompanied by generalized spike-wave consistent with IGE per adjudication review
  • A clear history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review
• Availability of a complete medication history since initiation of treatment, including doses and date of initiation
• No competing cause of epilepsy (e.g. traumatic brain injury)
• AED treatment (for seizures) instituted not more than 12 months before enrollment
• Age ≥13 years at time of enrollment
• Age ≥8 years at time of seizure onset
• Clinical seizure(s) and history consistent with IGE. The only permitted seizure types are absence, myoclonus or generalized tonic-clonic convulsions
• Patients must have had one of the following:
  • GTCSs alone accompanied by generalized spike-wave consistent with IGE per adjudication review
  • GTCSs with a history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review
  • GTCSs associated with a history of absence and/or myoclonus, not accompanied by generalized spike-wave consistent with IGE per adjudication review
  • A clear history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review
• Availability of a complete medication history since initiation of treatment, including doses and date of initiation
• No competing cause of epilepsy (e.g. traumatic brain injury)
• Two years of well-controlled seizures.
  • No convulsive seizures in the last two years
  • Myoclonic or absence seizures must be rare (\<2 per year) and non-disabling
  • Ongoing therapy with \> 1 antiseizure medication
• Age ≥13 years at time of enrollment
• Age ≥8 years at time of seizure onset
• Clinical seizure(s) and history consistent with IGE. The only permitted seizure types are absence, myoclonus or generalized tonic-clonic convulsions
• Occurrence of at least 1 seizure of any type in the 6 months prior to treatment onset
• Patients must have had one of the following:
  • GTCSs alone accompanied by generalized spike-wave consistent with IGE per adjudication review
  • GTCSs with a history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review
  • GTCSs associated with a history of absence and/or myoclonus, not accompanied by generalized spike-wave consistent with IGE per adjudication review
  • A clear history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review
• Availability of a complete medication history since initiation of treatment. This should include doses and date of initiation if possible, but minimum information would include name of drug, approximate duration of administration and reason for discontinuation, if applicable.
• No competing cause of epilepsy (e.g. traumatic brain injury)
• Treatment resistant IGE
  • Initiation of treatment at least 2 years prior to enrollment
  • Treatment resistance, as defined by failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination to achieve seizure freedom). ASMs taken at enrollment would count towards this minimum.
  • Either or both of the following two:
  • One GTCC per year over the last 2 years. ii. Any type of seizure at least every 3 months which can consist of either: disabling myoclonus or absence (in the opinion of the subject and investigator) or GTCC d. Such seizures were not primarily due to significant illness (e.g, URI is not significant unless temperature \>101oF (38.3oC), nonadherence to antiseizure medications or \>2 alcoholic beverages within 48 hrs of seizure e. Ongoing therapy with \> 1 antiseizure medication

Criteria the registry did not label

• Cohort 1: Newly Diagnosed IGE